Characterisation of the macroporosity of polycaprolactone-based biocomposites and release kinetics for drug delivery.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 17659772.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Microporous, biocomposite matrices comprising a continuous phase of poly(epsilon-caprolactone) (PCL) and a dispersed phase of lactose or gelatin particles with defined size range (45-90, 90-125 and 125-250 microm) were produced by precipitation casting from solutions of PCL in acetone. Scanning electron microscopy (SEM) analysis revealed a characteristic surface morphology of particulates interspersed amongst crystalline lamellae of the polymer phase. Rapid release of around 80% of the lactose content occurred in PBS at 37 degrees C in 3 days, whereas biocomposites containing gelatin particles of size range 90-125 and 125-250 microm, respectively, displayed gradual and highly efficient release of around 90% of the protein phase over 21 days. A highly porous structure was obtained on extraction of the water-soluble phase. Micro-computed tomography (Micro-CT) and image analysis enabled 3-D visualisation and quantification of the internal pore size distribution. A maximum fractional pore area of 10.5% was estimated for gelatin-loaded matrices. Micro-CT analysis confirmed the presence of an extensive system of macropores, sufficiently connected to permit protein diffusion, but an absence of high volume, inter-pore channels. Thus tissue integration would be confined to the matrix surface initially if the designs investigated were used as tissue-engineering scaffolds, with the core potentially providing a depot system for controlled delivery of growth factors.
Medical subject headings
- Biocompatible Materials
- Delayed-Action Preparations
- Drug Carriers
- Lactose
- Polyesters